Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Intangibles (2020 - 2025)

Moleculin Biotech (MBRX) has 3 years of Intangibles data on record, last reported at $11.1 million in Q4 2022.

  • For Q4 2022, Intangibles changed 0.0% year-over-year to $11.1 million; the TTM value through Dec 2022 reached $11.1 million, changed 0.0%, while the annual FY2022 figure was $11.1 million, 0.0% changed from the prior year.
  • Intangibles reached $11.1 million in Q4 2022 per MBRX's latest filing, roughly flat from $11.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $11.1 million in Q4 2020 and bottomed at $11.1 million in Q4 2020.
  • Average Intangibles over 3 years is $11.1 million, with a median of $11.1 million recorded in 2020.
  • The widest YoY moves for Intangibles: up 0.0% in 2021, down 0.0% in 2021.
  • A 3-year view of Intangibles shows it stood at $11.1 million in 2020, then changed by 0.0% to $11.1 million in 2021, then changed by 0.0% to $11.1 million in 2022.
  • Per Business Quant database, its latest 3 readings for Intangibles were $11.1 million in Q4 2022, $11.1 million in Q4 2021, and $11.1 million in Q4 2020.